Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Research & Development (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Research & Development for 10 consecutive years, with $42.0 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 2.1% to $42.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $167.3 million through Dec 2025, down 29.68% year-over-year, with the annual reading at $167.3 million for FY2025, 29.68% down from the prior year.
  • Research & Development for Q4 2025 was $42.0 million at Rhythm Pharmaceuticals, down from $46.0 million in the prior quarter.
  • The five-year high for Research & Development was $128.7 million in Q1 2024, with the low at $19.9 million in Q1 2021.
  • Average Research & Development over 5 years is $37.7 million, with a median of $33.0 million recorded in 2022.
  • The sharpest move saw Research & Development skyrocketed 239.08% in 2024, then crashed 71.26% in 2025.
  • Over 5 years, Research & Development stood at $31.6 million in 2021, then dropped by 25.42% to $23.5 million in 2022, then rose by 26.94% to $29.9 million in 2023, then surged by 37.72% to $41.2 million in 2024, then increased by 2.1% to $42.0 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $42.0 million, $46.0 million, and $42.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.